| [ Summary ] |
Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking. Conventional drugs including 5-ASA, corticosteroids, and purine analogues have been used anecdotally to treat intestinal BD. However, the clinical evidence regarding the management of intestinal BD is very limited. Recently, infliximab (IFX) and adalimumab (ADA) were approved for treatment of intestinal BD in Japan. Based on high efficacy and safety of TNF-α inhibitors in patients with intestinal BD, they are therapeutic options and should be considered as a standard therapy. Very recently, consensus-based practice guidelines for the management of intestinal BD have been renewed in light of the current clinical settings. This is an overview article of medical agents for intestinal BD in the renewed consensus statements focusing on the indication of anti-TNF-α mAbs. |